Gan&Lee
Gan&Lee is a high-tech biopharmaceutical enterprise integrating research
Gan & Lee Pharmaceutical Co., Ltd. was established in 1998, is a high-tech biopharmaceutical enterprise integrating research, development, production and sales. The company is a leading company at home and abroad in the development, research and production of biosynthetic human insulin and its analogs, and is a professional company focusing on biosynthetic human insulin analogs.
Innovative Drug Developer Rezu Bio Raised CNY 10 Mn in Series Pre-A
Ganli pharmaceutical won the bid for centralized procurement of insulin glargine injection
Cellatopia Secures Nearly CNY Ten Mn in Seed Funding
EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).
Apr 18, 2024 01:25 PM
Haier Biomedical 'Smart Blood City Network' Lands in Brazil
Brazil, as the largest country and economy in South America, faces numerous challenges brought about by an aging population. With the country's economy continuing to grow, healthcare issues are receiving increasing attention, and the demand for medical services is rising year by year.
Apr 15, 2024 03:45 PM
Special national collection of insulin: Ganli pharmaceutical Ganjing and asparagus insulin all reported the lowest prices: 48.71 yuan and 19.98 yuan
Robin Li: Baidu has become the world's largest automated driving service provider.
D3 Bio Completes A+ Round Financing, Accelerates Development of Product Pipeline
EqualOcean has learned that on April 8, 2024, D3 Bio(德昇济医药), a biotechnology company focused on the development and commercialization of innovative cancer and immune precision therapies, announced the successful completion of its A+ round financing led by Medicxi, a prominent European life sciences investment firm. The financing amounted to USD 62 million, with existing investor, Matrix Partners(经纬创投), also participating.
Apr 12, 2024 06:05 PM
During the 14th Five Year Plan period, China will restore 230 million mu of degraded grassland
Pharmaceutical and biological stocks fell sharply in early trading